UAE MSD GCC’s Ashraf Mallak looks back on a “transformational” two years since his last PharmaBoardroom interview back in 2021, with the set up of a new regional office, a raft of new launches and expanded indications, and the landmark inclusion of its HPV vaccine on various national immunization programs. Mallak…
Hong Kong MSD’s managing director for Hong Kong and Macau, Vincent Tong, came to lead the affiliate during the COVID-19 pandemic. He outlines the challenges and opportunities of a challenging time, discusses the leading position of the company’s cancer treatment Keytruda and his efforts as board member of the Hong Kong Association…
UAE MSD GCC’s new memorandum of understanding (MoU) with The Department of Health Abu Dhabi (DoH) aims to advance research into breast and lung cancer. The deal, signed at the BIO International Convention 2023, marks the continuation of a long-term collaboration between the two entities. Present at the signing were…
Greece Managing Director of MSD Greece, Cyprus & Malta Agata Jakoncic, who also serves as president of Greece’s PhRMA Innovation Forum (PIF), draws on her three decades of industry experience to outline some of the key challenges in the Greek pharma market today which threaten its sustainability and the ability of…
LatAm Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and unmet medical needs. Aiosa describes the myriad public-private partnerships that the firm has struck in LatAm across areas including cancer…
Singapore MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants will turn out MSD’s immunotherapy for cancer and its human papillomavirus (HPV) vaccine for the Asia-Pacific region. The reason we…
Egypt MSD’s managing director for Egypt, Libya, Sudan and Yemen, Hazem Abdel Samie, shares his perspective on recent changes within the American multinational and explains why Egypt’s move from a predominantly out-of-pocket market to a public system will open up many new opportunities. He also offers his view on the possibility…
Italy Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the Italian affiliate’s Equity and Inclusion initiatives. Since the Organon spinoff, the strategy to focus on specific parts of the portfolio…
Saudi Arabia After almost two decades with MSD, Ashraf Mallak, managing director for the company in the GCC region, dives into the often-overlooked healthcare capabilities of the Gulf countries, including the fact that certain products approved by the US FDA can sometimes be available in the region in as little as one…
Turkey After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence of chronic disease, strong national immunization program and increasing life expectancy. Its general manager for the Turkey cluster, Gözde Güllüoğlu,…
Denmark MSD’s Catherine Williams, a recent arrival in Copenhagen, gives her first impressions of the Danish healthcare system and pharma market, drawing on experiences in her native UK to compare the two countries’ market access environments for innovative products. Williams also touches on MSD’s sizeable clinical trial footprint in Denmark, the…
China MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its strategically important China business. van Acker takes the helm against the backdrop of change at MSD, with a new global CEO and the abandonment of the company’s COVID-19 vaccine projects.…
See our Cookie Privacy Policy Here